BCR-ABL1转录本类型影响一线伊马替尼治疗的费城染色体阳性慢性髓性白血病患者的缓解与结局
该研究分析了3项前瞻性研究共559例新诊断成人慢性髓性白血病患者,比较e13a2与e14a2转录本类型对一线伊马替尼治疗反应及临床结局的影响。e14a2患者分子学缓解更快更深,7年总生存、无进展生存和无失败生存均显著优于e13a2患者。结论认为e13a2转录本患者分子学反应较慢、缓解率较低且长期结局较差。
要点
- e14a2患者达到MR3.0和MR4.0的中位时间显著短于e13a2患者。
- e14a2患者7年总生存、无进展生存和无失败生存均显著优于e13a2患者。
- e13a2转录本患者分子学反应较慢、缓解率较低且长期结局较差。
核心结论
- e13a2转录本患者分子学反应较慢、对伊马替尼的缓解率较低且长期结局较差。
研究设计与样本
- 分析3项前瞻性研究(NCT00514488、NCT00510926、观察性研究CML/023)共559例新诊断成人慢性髓性白血病患者,基线行定性PCR检测BCR-ABL1转录本类型。
- 52%患者为e14a2转录本,37%为e13a2转录本,11%同时表达两种转录本,1%为其他罕见转录本。
- 中位随访76个月,95%的患者至少有5年观察。
主要发现
- e14a2与e13a2患者的完全细胞遗传学缓解率相当。
- e14a2患者达到MR3.0的中位时间(6个月和12个月)和MR4.0的中位时间(41个月和61个月)均显著短于e13a2患者。
- e14a2患者MR3.0累积概率为88%,e13a2患者为83%(P < .001)。
- e14a2患者MR4.0累积概率为67%,e13a2患者为52%(P = .001)。
- e14a2患者7年总生存为90%,e13a2患者为83%(P = .017);无进展生存为89%对81%(P = .005);无失败生存为71%对54%(P < .001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The most frequent BCR-ABL1 fusion transcripts in chronic myeloid leukemia (CML) are the e13a2 (b2a2) and the e14a2 (b3a2) ones. In the imatinib era few studies addressing the prognostic significance of the BCR-ABL1 transcript type in early chronic phase CML have been published. Overall, these studies suggest that in e14a2 patients the response to imatinib is faster and deeper. To evaluate if the BCR-ABL1 transcript type (e13a2 compared to e14a2) affect the response to imatinib and the clinical outcome in newly diagnosed adult CML patients, 559 patients enrolled in 3 prospective studies (NCT00514488, NCT00510926, observational study CML/023) were analyzed. A qualitative PCR was performed at baseline: 52% patients had a e14a2 transcript, 37% a e13a2 transcript, 11% co-expressed both transcripts and 1% had other rare transcripts. The median follow-up was 76 months (95% of the patients had at least a 5-year observation). The complete cytogenetic response rates were comparable in e14a2 and e13a2 patients. The median time to MR3.0 (6 and 12 months) and MR4.0 (41 and 61 months) was significantly shorter for e14a2 patients compared to e13a2 patients, with a higher cumulative probability of MR3.0 (88% and 83%, P < .001) and MR4.0 (67% and 52%, P = .001). The 7-year overall survival (90% and 83%, P = .017), progression-free survival (89% and 81%, P = .005) and failure-free survival (71% and 54%, P < .001) were significantly better in patients with e14a2 transcript. In conclusion, patients with e13a2 transcript had a slower molecular response with inferior response rates to imatinib and a poorer long-term outcome.
引用
- Castagnetti F, Gugliotta G, Breccia M, et al. The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib. Am J Hematol. 2017. PMID: 28466557. doi:10.1002/ajh.24774
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。